CSHL scientists correlate enzyme expression levels with chemotherapy dru... ( Why do cancer patients develop resis...)

CSHL scientists correlate enzyme expression levels with chemotherapy drug response

Date:7/18/2008

Why do cancer patients develop resistance to chemotherapy drugs, sometimes abruptly, after a period in which the drugs seem to be working well to reduce tumors or hold them in check? Although largely a mystery to scientists, the result when this occurs is all too familiar: patients relapse and in many cases die when their cancers become resistant.

A team of researchers at Cold Spring Harbor Laboratory (CSHL), seeking to understand the genetic underpinnings of cancer therapy response, have identified what they regard a "significant contributor to resistance." Using a novel screening technique involving "pools" of gene-regulating short RNA molecules, they were able to determine how resistance to a drug called doxorubicin arises in lymphomas occurring in a particular strain of mice.

Toward a "global view" of factors influencing therapy response

"The method we developed is notable," said CSHL Professor Scott W. Lowe, Ph.D., a leader of the research team, "because it gives us a view of how resistance works at the level of individual molecules in living animals, and also because it can be easily extended to other chemotherapy drugs and tumor systems to give a potentially global view of factors that mediate response to cancer therapy."

Many genetic factors are already known to influence the effectiveness of anti-cancer drugs. Such factors manifest themselves in a variety of ways, some of them remarkable. One known gene change, for instance, results in increased expression of pump-like mechanisms that remove chemotherapeutic toxins from cancer cells; another causes changes in cellular structure that prevent drug molecules from "docking" with their targets.

The research by the CSHL team, which included Professors W. Richard McCombie, Ph.D., and Gregory J. Hannon, Ph.D., in addition to Dr. Lowe, demonstrated the mechanism of one form of resistance in cell culture and living mice. These results were reported in Proce
'/>"/>

Contact: Jim Bono
bono@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds

Post Your Comments:

(Date:6/19/2013)... Quapaw, OK (PRWEB) June 19, 2013 ... of Companies, including RWI Benefits, LLC, Native Care ... The National Association of Health Underwriters’ (NAHU) new ... Affordable Care Act (PPACA). This continuing education course ... states, and Roberson will receive eleven education credits ...

(Date:6/19/2013)... According to a June 17, 2013 Allure ... is not uncommon for a person to suffer from a ... is likely to forget to reapply sunscreen properly and end ... and itchy. When this occurs, it is essential to act ... people do not realize that milk contains proteins, fats, and ...

(Date:6/19/2013)... In a major international study led by researchers at ... targeted therapy ibrutinib continues to show remarkable promise for ... (MCL). , The most recent interim findings of the ... New England Journal of Medicine . Previous interim ... American Society of Hematology Annual Meeting and Exposition. ...

(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...

(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...

Breaking Medicine News(10 mins):Health News:RWI Benefits, LLC Becomes PPACA Certified 2 Health News:Skin Care – How to treat Sunburn 2 Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2 Health News:Neurosurgery publishes findings of 3 important studies in June issue 2 Health News:Neurosurgery publishes findings of 3 important studies in June issue 3 Health News:States vary widely on success rates for minorities in drug treatment programs 2 Health News:States vary widely on success rates for minorities in drug treatment programs 3

[0] RWI Benefits, LLC Becomes PPACA Certified [0] Skin Care – How to treat Sunburn [0] Ibrutinib continues strong showing against mantle cell lymphoma [0] Neurosurgery publishes findings of 3 important studies in June issue [0] States vary widely on success rates for minorities in drug treatment programs

... Dec. 1 Acuo Technologies(R), developers,of high-performance software ... services, today announced the contracting with Rush,University ... new vendor neutral archiving,solution which becomes the basis ... archiving solution is based on the Acuo Technologies ...

... In recognition of World AIDS Day, Charlotte Bobcats, Emeka Okafor, will ... One Million African Lives Initiative (OMALI), a program of the Safe ... is to save one million lives in Africa by 2011 by ... , , OMALI will be ...

... TOMS Shoes, the philanthropic,footwear company, has launched a ... and Give More this holiday season. For 30,days, from ... to help give 30,000 pairs of shoes to children ... preventable by wearing shoes. By,purchasing a pair of shoes ...

... , , ANN ARBOR, ... pajamas or a video game are all quick and easy gifts to ... not give something more healthy and beneficial to a loved one? Why ... Staying healthy around the holidays can be challenging, and this ...

... Dec. 1 TorreyPines Therapeutics, Inc.,(Nasdaq: ... administration of NGX426, an,AMPA/kainate-type glutamate receptor antagonist, ... hyperalgesia (abnormally increased,pain state) and allodynia (pain ... compared to placebo following intradermal injections of ...

... Horvath, D.V.M., as Vice President of Preclinical Sciences and ... , CAMBRIDGE, Mass., Dec. ... Mass.-based executive team with the appointment of Jeffrey T. ... announced the additions of Christopher Horvath, D.V.M., as vice ...

Cached Medicine News:Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 2 Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 3 Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2 Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2 Health News:Giving the Gift of Health This Holiday Season 2 Health News:Giving the Gift of Health This Holiday Season 3 Health News:Giving the Gift of Health This Holiday Season 4 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4 Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5 Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2 Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3

Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days!Giving the Gift of Health This Holiday Season TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

(Date:6/19/2013)... BURLINGTON, Mass. , June 19, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... the majority of surveyed U.S. and European rheumatologists ... of the attributes that most influences their prescribing ... U.S. and European rheumatologists, respectively, rank the percentage ...

(Date:6/19/2013)... , June 19, 2013 BD Biosciences, a segment ... ), a leading global medical technology company, today announced the ... the latest in its line of high-performance research flow cytometers. ... high-performance multicolor analysis with the most compact footprint in its ... and a height of 30" (76.2 cm). Recognizing that space ...

(Date:6/19/2013)... PRINCETON, N.J. , June 19, 2013 ... Belrose Pharma, a new specialty pharmaceutical company ... generation of innovative injectable and sustained release ... high unmet medical needs, today announced the ... (Customized Linker Technology®) platform and associated product ...

Breaking Medicine Technology:U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2 New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3 Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4

[0] U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis [0] New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research [0] Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies

... YORK, Oct. 24, 2011 Reportlinker.com ... report is available in its catalogue: ... to 2017 - Glaucoma and Cataract ... Ophthalmic Surgery to Drive the Ophthalmic ...

... 2011 Phreesia, the patient check-in company, is committed ... practices nationwide with its electronic self-service check-in solution. One ... for practices is by automating the eligibility and benefits ... accurate billing by confirming coverage prior to the exam. ...

Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market Phreesia Continues to Enhance its Market-Leading Eligibility and Benefits Verification Process for Medical Practices

... to provide excellent protection and ease of ... being closer to an adhesive in molecular ... CoEase to maintain viscosity at high shear ... worlds for superb performance during capsulorhexis, phaco, ...

... viscosurgical device is a cohesive ... high molecular weight, high pseudoplasticity, ... provides excellent space maintenance, facilitates ... removed. It is available in ...

... VISUCAM DigitalCameras permit fundus imaging and ... operation without any need for eyepieces ... findings. Image recording and display is ... utilizes the ophthalmoscope principle of modern ...

... The ARIS A utomated R ... revolutionary, patented technology which provides rapid and automated ... allows eye care professionals to screen and ... in less time and at ...

Medicine Products:

CoEase ProVisc VISUCAM Digital Camera ARIS Automated Retinal Imaging System